Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 157

1.

Targeting Regulation of Cyclin Dependent Kinase 9 as a Novel Therapeutic Strategy in Synovial Sarcoma.

Li X, Seebacher NA, Xiao T, Hornicek FJ, Duan Z.

J Orthop Res. 2018 Nov 28. doi: 10.1002/jor.24189. [Epub ahead of print]

PMID:
30488489
2.

RNA sequencing (RNA-Seq) and its application in ovarian cancer.

Wang J, Dean DC, Hornicek FJ, Shi H, Duan Z.

Gynecol Oncol. 2018 Oct 5. pii: S0090-8258(18)31283-6. doi: 10.1016/j.ygyno.2018.10.002. [Epub ahead of print] Review.

PMID:
30297273
3.

Application of liquid biopsy in bone and soft tissue sarcomas: Present and future.

Li X, Seebacher NA, Hornicek FJ, Xiao T, Duan Z.

Cancer Lett. 2018 Dec 28;439:66-77. doi: 10.1016/j.canlet.2018.09.012. Epub 2018 Sep 14.

PMID:
30223067
4.

From genomics to metabolomics: emerging metastatic biomarkers in osteosarcoma.

Dean DC, Shen S, Hornicek FJ, Duan Z.

Cancer Metastasis Rev. 2018 Aug 31. doi: 10.1007/s10555-018-9763-8. [Epub ahead of print] Review.

PMID:
30167827
5.

MiR-139-5p is associated with poor prognosis and regulates glycolysis by repressing PKM2 in gallbladder carcinoma.

Chen J, Yu Y, Chen X, He Y, Hu Q, Li H, Han Q, Ren F, Li J, Li C, Bao J, Ren Z, Duan Z, Cui G, Sun R.

Cell Prolif. 2018 Dec;51(6):e12510. doi: 10.1111/cpr.12510. Epub 2018 Aug 13.

PMID:
30105813
6.

Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.

Liao Y, Sassi S, Halvorsen S, Feng Y, Shen J, Gao Y, Cote G, Choy E, Harmon D, Mankin H, Hornicek F, Duan Z.

Sci Rep. 2018 Aug 9;8(1):12107. doi: 10.1038/s41598-018-30644-x.

7.

Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer.

Wang J, Garbutt C, Ma H, Gao P, Hornicek FJ, Kan Q, Shi H, Duan Z.

Gynecol Oncol. 2018 Jul;150(1):143-150. doi: 10.1016/j.ygyno.2018.04.557. Epub 2018 Apr 24.

PMID:
29699801
8.

CRISPR-Cas9-Mediated Silencing of CD44 in Human Highly Metastatic Osteosarcoma Cells.

Liu T, Yan Z, Liu Y, Choy E, Hornicek FJ, Mankin H, Duan Z.

Cell Physiol Biochem. 2018;46(3):1218-1230. doi: 10.1159/000489072. Epub 2018 Apr 16.

9.

Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma.

Li X, Seebacher NA, Garbutt C, Ma H, Gao P, Xiao T, Hornicek FJ, Duan Z.

Cell Death Dis. 2018 May 1;9(5):446. doi: 10.1038/s41419-018-0474-4.

10.

Expression and Clinical Implication of Autophagy-Associated Protein p62 in Osteosarcoma.

Ma H, Li X, Wang J, Hornicek FJ, Garbutt CC, Chang X, Duan Z.

Oncology. 2018;95(1):52-60. doi: 10.1159/000487437. Epub 2018 Apr 4.

11.

Targeting DYRK1B suppresses the proliferation and migration of liposarcoma cells.

Chen H, Shen J, Choy E, Hornicek FJ, Shan A, Duan Z.

Oncotarget. 2017 Nov 28;9(17):13154-13166. doi: 10.18632/oncotarget.22743. eCollection 2018 Mar 2.

12.

HER4 promotes cell survival and chemoresistance in osteosarcoma via interaction with NDRG1.

Wang H, Sun W, Sun M, Fu Z, Zhou C, Wang C, Zuo D, Zhou Z, Wang G, Zhang T, Xu J, Chen J, Wang Z, Yin F, Duan Z, Hornicek FJ, Cai Z, Hua Y.

Biochim Biophys Acta Mol Basis Dis. 2018 May;1864(5 Pt A):1839-1849. doi: 10.1016/j.bbadis.2018.03.008. Epub 2018 Mar 8.

PMID:
29524631
13.

Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma.

Zhou Y, Shen JK, Yu Z, Hornicek FJ, Kan Q, Duan Z.

Biochim Biophys Acta Mol Basis Dis. 2018 May;1864(5 Pt A):1573-1582. doi: 10.1016/j.bbadis.2018.02.004. Epub 2018 Feb 13.

PMID:
29452249
14.

Advances in chromosomal translocations and fusion genes in sarcomas and potential therapeutic applications.

Xiao X, Garbutt CC, Hornicek F, Guo Z, Duan Z.

Cancer Treat Rev. 2018 Feb;63:61-70. doi: 10.1016/j.ctrv.2017.12.001. Epub 2017 Dec 6. Review.

PMID:
29247978
15.

CDK4 expression in chordoma: A potential therapeutic target.

Liu T, Shen JK, Choy E, Zhang Y, Mankin HJ, Hornicek FJ, Duan Z.

J Orthop Res. 2018 Jun;36(6):1581-1589. doi: 10.1002/jor.23819. Epub 2017 Dec 22.

PMID:
29194728
16.

Advances in sarcoma gene mutations and therapeutic targets.

Gao P, Seebacher NA, Hornicek F, Guo Z, Duan Z.

Cancer Treat Rev. 2018 Jan;62:98-109. doi: 10.1016/j.ctrv.2017.11.001. Epub 2017 Nov 11. Review.

PMID:
29190505
17.

Novel strategies to prevent the development of multidrug resistance (MDR) in cancer.

Wang J, Seebacher N, Shi H, Kan Q, Duan Z.

Oncotarget. 2017 Jul 12;8(48):84559-84571. doi: 10.18632/oncotarget.19187. eCollection 2017 Oct 13. Review.

18.

Noncoding RNA in drug resistant sarcoma.

Li X, Shen JK, Hornicek FJ, Xiao T, Duan Z.

Oncotarget. 2017 Jul 6;8(40):69086-69104. doi: 10.18632/oncotarget.19029. eCollection 2017 Sep 15. Review.

19.

Regulation of microRNAs function by circular RNAs in human cancer.

Han C, Seebacher NA, Hornicek FJ, Kan Q, Duan Z.

Oncotarget. 2017 Aug 4;8(38):64622-64637. doi: 10.18632/oncotarget.19930. eCollection 2017 Sep 8. Review.

20.

An Update on Circumventing Multidrug Resistance in Cancer by Targeting P-Glycoprotein.

Yang X, Li X, Duan Z, Wang X.

Curr Cancer Drug Targets. 2018;18(7):677-696. doi: 10.2174/1568009617666170623114524.

PMID:
28820055

Supplemental Content

Loading ...
Support Center